UK MHRA approves Vertex's Casgevy for children aged five and older

The UK's MHRA granted approval for Vertex Pharmaceuticals' gene-editing therapy Casgevy to treat children aged five and older with severe sickle-cell disease and transfusion-dependent beta-thalassemia. The therapy was previously authorized only for patients aged 12 and older.

Detected & updated continuously · Source: Nebula